Who is sponsoring NCT03847558?

NCT03847558 is sponsored by Assiut University.

What condition does NCT03847558 study?

NCT03847558 studies β-Thalassemia Major Patients Receiving Chelation Therapy.

Is NCT03847558 still recruiting?

NCT03847558 is currently status unknown. Last updated 20 February 2019.

Last reviewed 2019-02-20 · How we verify

NCT03847558

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Sexual Maturation in β-Thalassemia Major Patients in Assiut University Hospital

Status unknown Last updated 20 February 2019

What this trial tests

trial testing FSH((Follicle Stimulating Hormone) and LH (Luteinizing Hormone) hormone for females and Testosterone hormone for males in β-Thalassemia Major Patients Receiving Chelation Therapy in 100 participants. Status unknown.

Timeline

15 April 2019

Primary endpoint
15 April 2020

15 April 2020

Quick facts

Lead sponsor	Assiut University
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	100
Start date	15 April 2019
Primary completion	15 April 2020
Estimated completion	15 April 2020

Drugs / interventions tested

FSH((Follicle Stimulating Hormone) and LH (Luteinizing Hormone) hormone for females and Testosterone hormone for males

Conditions studied

β-Thalassemia Major Patients Receiving Chelation Therapy — all drugs for β-Thalassemia Major Patients Receiving Chelation Therapy →

Sponsor

Assiut University

Who can join

Adults 10 to 16, any sex, with β-Thalassemia Major Patients Receiving Chelation Therapy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

cross sectional study to asses sexual maturation in β-Thalassemia Major patients receiving Iron Chelation Therapy in assuit University Hospital and maintenance of 2ry sexual characters and reproduction

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Assiut University trials

Trials by the same sponsor.

NCT07423312 — Lead Exposure and Multiple Sclerosis · not yet recruiting
NCT07234526 — Usage of Glucose Fluctuations as a Prognostic Marker in Septic Shock Patients · not yet recruiting
NCT07273214 — Knowledge, Attitude and Practice of Third Trimester Pregnant Mothers Towards Self-Medication in Assiut, Egypt · not yet recruiting
NCT07194863 — Efficacy of Essential Phospholipid Versus Betaine HCL/L-Glutamic Acid in MAFLD · not yet recruiting
NCT07053709 — Screening for Hyperuricemia in Patients With Metabolic Associated Fatty Liver Disease (MAFLD) · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03847558 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Assiut University
Last refreshed: 20 February 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03847558.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing